The Sunday Times | October 2, 2021
“Even in high-income countries all the leverage is based in the pharmaceutical industry because you’ve got a perfect combination for them of supply scarcity, huge demand and enormous political pressure to vaccinate the population, with tens of thousands in any given country dying and the economy tanking,” Lawrence Gostin, professor of global health law at Georgetown University, says. “This isn’t a fair negotiation. This is something where a pharmaceutical company holds all the cards.”